# Next Session — Session 65: C11 Parallel-Write + Drug Card Sprint 1

**Prepared:** 2026-05-26  
**Phase:** Phase 6 — Intelligence Presentation Layer  
**Session 64 complete:** C1/C2 migration ✅ · write_meridian ailux_angle fix ✅ · company surface audit ✅ · enrichment observability design ✅

---

## Session 64 — What Was Done

### WS-A — C1/C2 Drug Modal Migration (COMPLETE)
- `drug_area_scores` reads at lines 11677 (C1) and 11761 (C2) replaced with `drug_competitive_scores`
- `SELECT` updated: `context_type,context_id,overlap,overlap_rationale,cls,confidence_level,source_url,vs_ailux`
- `drug_areas` join removed — `scoreRes0.data` is now the complete source
- `areas[]` reshaped: `context_id` exposed as `area_id` for downstream compat; `vs_ailux` carried forward
- Dual-read comparison harness inserted after C1 fetch: `window.__MERIDIAN_COMPETITIVE_SCORE_COMPARE__`
- `_confBadge` updated to handle new A/B/C enum alongside legacy confirmed/supported
- `_CONF_LABEL` tooltip map added
- `_CEM_AMAP` extended: added `uc:'UC'`, `cd:'CD'`, `ted:'TED'`, `autoimmune:'Autoimmune'`
- `_AREA_LABEL` extended: added `ibd`, `uc`, `cd`, `ted`, `autoimmune`, `respiratory`

### WS-C — write_meridian.py ailux_angle Fix (COMPLETE)
- `ailux_angle` and `overlap_rationale` added to `fetch_drug_context()` SELECT
- `BD Signal: {ailux_angle}` line added to `enrich_intel_with_drug_context()` drug context block
- 130 enriched drug-level angles now available to daily Meridian briefing context

### WS-E — Company Surface Inventory (COMPLETE)
- Three surfaces identified and classified
- Inventory doc: `docs/company_surface_inventory_session64.md`
- Surface A (`openCompanySlideOver` → entity-modal): CANONICAL — all new intelligence goes here
- Surface B (`#co-slideover`): DEAD LEGACY — no JS writes to it; safe to remove
- Surface C (`openCOPanel` → `#co-panel`): PARALLEL — redirect to canonical in Session 66+

### WS-D — Enrichment Observability Design (COMPLETE)
- Full `enrichment_runs` table DDL designed
- `EnrichmentRunLogger` class designed for `company_enrichment.py`
- `ResearchRunLogger` designed for `research.py`
- nightly_health_report.py additions specified (5 new count queries)
- Implementation doc: `docs/enrichment_observability_plan_session64.md`

---

## Session 64 — Acceptance Criteria Check

| Criterion | Status |
|---|---|
| Drug modal reads competitive context from drug_competitive_scores | ✅ C1/C2 done |
| Legacy drug_area_scores no longer used for C1/C2 display | ✅ |
| C4-C8 legacy provenance reads remain untouched | ✅ Not touched |
| All six feature flags remain true | ✅ Not touched |
| Drug-level ailux_angle available to briefing context | ✅ write_meridian.py patched |
| Company surface inventory complete | ✅ 3 surfaces classified |
| sim0500/spy072 false backfill task removed | ✅ Removed below |

---

## Immediate On-Open (Session 65)

### Validation checks

```sql
-- 1. Check drug_validation_results (standing rule — do this first)
SELECT check_name, result, details
FROM drug_validation_results
WHERE result IN ('fail', 'warning', 'needs_review')
ORDER BY result, check_name;
-- Expected: 0 fail, 5 pre-existing needs_review. Any new entries = investigate first.

-- 2. Confirm dual-read harness is live — open any TL1A drug modal in browser
-- Expected console output: [MERIDIAN_CMP] OK: {drug_name} old=1 new=1 matched=1
-- Or for IBD drug: old=1 new=2 ibd_expansion=true

-- 3. Confirm ailux_angle in meridian briefing context
-- Expected: next write_meridian.py run includes "BD Signal:" lines in drug context
```

### C1/C2 10-drug validation set

Open each in the drug modal and confirm: no `?` badges on previously-confirmed drugs, area chips display `UC`/`CD`/`TED` correctly for IBD/TED drugs.

| Drug | Expected context_ids | IBD expansion? |
|---|---|---|
| sim0709 | uc, cd | yes |
| batoclimab | fcrn | no |
| dupilumab | il4ra | no |
| risankizumab | uc, cd | yes |
| efgartigimod | fcrn | no |
| riliprubart | fcrn | no |
| epi-001 | ibd (fallback) | no |
| upadacitinib | uc, cd | yes |
| spy072 | ibd (fallback — RA drug, intentional) | no |
| sim0500 | ibd (fallback — MM drug, intentional) | no |

---

## Session 65 — Primary Work

### P0: C11 Parallel-Write (company_enrichment.py → drug_competitive_scores)

**PREREQUISITE:** C1/C2 must be validated with no unexpected regressions before C11 starts.  
Per migration plan: C11 should begin after C1 is stable for ≥7 days. Session 65 is the right target.

**Tasks:**
1. Open `docs/drug_competitive_scores_consumer_inventory.md` — read Section 5 (C11 design)
2. Add parallel-write block to `company_enrichment.py` after each `drug_area_scores` upsert
3. Map `drug_area_scores` fields → `drug_competitive_scores` schema:
   - `area_id` → `context_type` + `context_id` (use area_id→context_type lookup table)
   - `confidence_level` → map confirmed→A, supported→B, inferred→inferred
   - `overlap`, `overlap_rationale`, `cls`, `source_url` → direct copy
   - `vs_ailux_positioning` → `vs_ailux`
4. Preserve existing `drug_area_scores` write — do NOT remove it
5. Run one enrichment pass for a single area (tl1a recommended)
6. Verify `drug_competitive_scores` row count increases
7. Confirm `enrichment_run_id` written where supported

**Acceptance criteria:**
- Every `drug_area_scores` upsert also writes a `drug_competitive_scores` row
- Row count in `drug_competitive_scores` ≥ row count in `drug_area_scores`
- `drug_area_scores` writes unchanged (legacy preserved)
- No C4–C8 behavior broken

---

## Session 65 — Secondary Work (parallel-safe after C11 is drafted)

### Drug Card Sprint 1 (WS-F)

Tables: `drugs`, `drug_targets`, `drug_indications`, `catalysts`, `companies`, `partnerships`, `drug_competitive_scores` (post-C1)

**Components to add to `_cemDrugBody`:**

1. **Ailux BD Signal** — `drugs.ailux_angle` (already fetched; render more prominently at top)
2. **Overlap tier badge** — `drugs.overlap` + `drugs.overlap_rationale` (rationale not currently rendered)
3. **Catalyst timeline** — fetch `catalysts WHERE canonical_drug_id = drug.id OR drug_id = drug.id`, show next 1–3 by sort_date
4. **Competitive cluster** — from `areas[]` (already fetched via drug_competitive_scores), group by context_id, show peer count
5. **Confidence indicator** — use `areas[0].confidence_level` for badge if available

**Do not add to drug card:**
- C3 PI tab features (behavioral consumer, not yet migrated)
- Hardcoded TL1A/IBD logic
- `drug_areas` reads

---

## Session 66 (Planned)

1. C11 monitoring — confirm 7+ days stable, no enrichment drift
2. Begin `enrichment_runs` table DDL application (from `docs/enrichment_observability_plan_session64.md`)
3. Begin Surface C redirect: `openCOPanel` → `openCompanySlideOver` (thin launcher)
4. Drug card Sprint 1 continuation: ownership chain + confidence badge

---

## Session 67 (Planned)

- C3 PI tab scoreRows migration (`_makeAreaPI`, line 12548): `drug_area_scores` → `drug_competitive_scores`
- HIGH RISK — behavioral consumer. Only after C11 parallel-write proven ≥7 days.
- Requires: area_id → context_id lookup map; behavioral validation across all 6 tabs

---

## Session 68 (Planned)

- WS-H: `company_strategic_views` + `company_platform_views` DDL + backfill
- These tables must exist before autoimmune/respiratory/tcell tabs can be retired from `drug_areas`

---

## Backlog (do not let these delay Session 65)

| Item | Status |
|---|---|
| sim0500/spy072 backfill to UC/CD | **REMOVED** — confirmed correct as ibd fallback (MM + RA drugs) |
| cizutamig TED ECC review | Open — determine if drug_indications(ted) entry needed |
| drug_validation_results HTTP 400 | Open — investigate RLS/service key access |
| Surface B (`#co-slideover`) DOM removal | Low priority cleanup |
| Tier 2 angles (18 drugs) | Accepted backlog |
| C9/C10 Ontology Audit tab migration | After C1 stable — low priority |

---

## Do Not

- Build new features into `openCOPanel` / `#co-panel` (Surface C — parallel legacy)
- Restore `#co-slideover` (Surface B — dead DOM)
- Remove `drug_area_scores` or `drug_areas` tables
- Migrate C3 before C11 is stable ≥7 days
- Backfill sim0500 or spy072 to UC/CD drug_indications
- Build new company intelligence outside `openCompanySlideOver` / entity-modal

---

## Modified Files — Session 64

| File | Change |
|---|---|
| `scripts/write_meridian.py` | Added `ailux_angle`, `overlap_rationale` to `fetch_drug_context()` SELECT; added `BD Signal:` line to drug context block |
| `index.html` | C1/C2 drug modal migrated to `drug_competitive_scores`; `_confBadge` updated (A/B/C enum); `_CONF_LABEL` added; `_CEM_AMAP` extended (uc/cd/ted); `_AREA_LABEL` extended (ibd/uc/cd/ted/autoimmune/respiratory); dual-read harness added |
| `docs/company_surface_inventory_session64.md` | New — company surface classification |
| `docs/enrichment_observability_plan_session64.md` | New — enrichment_runs design + implementation plan |

## Supabase Tables Touched — Session 64

None. All Session 64 work was frontend JS + Python script changes. No Supabase schema or data changes.

---

## What Is Now Safe to Build

| Feature | Safe? | Reason |
|---|---|---|
| Drug card: ailux_angle display | ✅ YES | drugs table, fully enriched |
| Drug card: overlap_rationale | ✅ YES | drugs table, fetched in _cemDrugBody |
| Drug card: catalyst timeline | ✅ YES | catalysts table, direct drug_id FK |
| Drug card: competitive context chips | ✅ YES | drug_competitive_scores now live in C1/C2 |
| Drug card: ownership chain | ✅ YES | companies + partnerships tables |
| Drug card: confidence badge | ✅ YES | drug_competitive_scores.confidence_level (A/B/C) |
| Company card: parent_company_id | ✅ YES | companies table, safe read |
| Homepage: catalyst feed | ✅ YES | catalysts table, direct query |
| PI tab competitive scoring features | ⏳ WAIT | C3 migration pending (Session 67) |
| Strategic/platform grouping by company | ⏳ WAIT | company_strategic_views not yet built (Session 68) |
